sefulness of contrast-enhanced ultrasound (CEUS) in Crohn’s disease pediatric patients

Not Applicable

Recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0005685
• Lead Sponsor: Yonsei University Health System, Severance Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 January 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Patients who are under the age of 18 with Crohn’s disease with colonoscopy within 2 years of IRB approval

Exclusion Criteria

Patients who are over the age of 18 and under the age of two
- Patients who did not under go colonoscopy
- Patients who have other bowel disease or mass than Crohn’s disease
- High allergic sensitivity to Sonovue injection agent or sulfur hexafluoride
- Patients who have right to left shunt, pulmonary hypertension, or systemic hypertension
- Patients who have end stage renal or liver disease or septic shock

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
feasibility of Contrast Enhanced Ultrasound (CEUS) in the assessment of Crohn’s disease (CD) without major adverse effect

Secondary Outcome Measures

Name	Time	Method
Check if contrast enhancement ultrasound can find lesions based on endoscopy.;Significant quantitative contrast enhancement ultrasonic parameters reflecting treatment